English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 28 January 2021, 09:50 HKT/SGT
Share:
China Biotech Services LY007 Cell Injection Obtained Clinical Trial Approval Letter
China's first and only CAR-T product with CD20 target approved for registration clinical application

HONG KONG, Jan 28, 2021 - (ACN Newswire) - China Biotech Services Holdings Limited ("CH BIOTECH SER" or "Company", stock code: 8037.HK) non-wholly-owned subsidiary Shanghai Longyao Biotechnology Co., Ltd. ( "Shanghai Longyao") received an approval letter from the National Medical Products Administration for a clinical trial of the Company's LY007 Cellular Injection on January 21, 2021, which is registered as a Class I new drug. LY007 Cellular Injection is mainly used for the treatment of non-Hodgkin lymphoma. It is currently the first and only CD20-targeted CAR-T product whose application for a registered clinical trial has been approved in China.

LY007 Cellular Injection is a chimeric antigen receptor T-cell (CAR-T) injection and is mainly used in the treatment of relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma and metastatic follicular lymphoma. LY007 Cellular Injection has beenwas developed independently by Shanghai Longyao and incorporates its patented OX40 co-stimulatory signal design. Experiments have proved that the design enhances the efficacy of the Product without compromising safety. According to the clinical trial application of LY007 Cellular Injection, Shanghai Longyao will commence Phase I clinical trial and study of LY007 Cellular Injection based on the submitted proposal.The National Medical Products Administration's approval of Shanghai Longyao's clinical trial application for LY007 Cellular Injection demonstrates Shanghai Longyao's capabilities in the research and development of immunocellular drugs.

According to a research report issued by China Merchants Bank on CH BIOTECH SER on November 20, 2020, the analyst recommended to watch for the results of the LY007 Cellular Injection clinical trial which could enhance the company's market value. The report also pointed out that the company's current market capitalization is slightly less than US$200 million while market capitalization of CAR-T comparable companies listed on the main board of the Hong Kong Stock Exchange is between US$600 million and US$1.4 billion. The current market value of CAR-T comparable Chinese companies listed on NASDAQ is approximately US$3.5 billion.


Topic: Press release summary
Source:

Sectors: Daily Finance, Daily News, BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2021 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
Glasstech Asia 2021 exhibition postponed to 26-28 October 2022  
June 23, 2021 16:06 HKT/SGT
Anticancer Agent "Tazverik Tablets 200mg" (Tazemetostat Hydrobromide) Approved In Japan For EZH2 Gene Mutation-positive Follicular Lymphoma  
June 23, 2021 14:20 HKT/SGT
DENSO Invests in Seurat Technologies to Accelerate Development of Metal Additive Manufacturing  
June 23, 2021 13:54 HKT/SGT
Blockpass Accepted to FCA Regulatory Sandbox  
June 23, 2021 13:00 HKT/SGT
Woven Alpha Automated Mapping Platform and Mitsubishi Fuso Collaborate on Latest HD Mapping Technology for Advanced Driver Assistance Systems Functionality  
June 23, 2021 12:38 HKT/SGT
Watch Borneo Jazz Festival Free This 25-27 June  
June 23, 2021 10:00 HKT/SGT
ILgamos going ILGON. New project, same goal.  
June 23, 2021 10:00 HKT/SGT
Fujitsu Demonstrates High Performance Simulations for Industrial Use Cases with Commercial Applications on the World's Fastest Supercomputer, Fugaku  
June 23, 2021 09:41 HKT/SGT
Fujitsu, City of Kawasaki Strengthen Cooperation to Realize a Sustainable "Future City"  
June 23, 2021 09:25 HKT/SGT
HYPEBEAST LTD. (0150.HK) Sees Record Profitability Despite Covid-19 Challenges, Looks Ahead To Growth  
June 22, 2021 21:03 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575